



Sagentia Partners with Senseonics to Develop Novel Connected Health Solution to Improve Diabetics' Lives

Boston, MA – September 23, 2013 – [Sagentia](#) Inc., a global technology and product development company, announced today that it has developed a medically regulated iPhone app for the [Senseonics](#) Glucose Monitoring System. The system has been designed to provide self-management assistance to diabetes patients and enable sufferers to live more confidently and easily.

The Senseonics Glucose Monitoring System consists of three major components: an implanted sensor; a wireless transmitter that communicates with the sensor; and a smartphone mobile medical application. After insertion, the system can function non-invasively, automatically and continuously for six months or longer before replacement. With this approach, glucose levels of a patient can be measured every few minutes with accurate and specific alerts being sent to both the user and their physician about impending hyperglycaemia (high blood sugar) and hypoglycaemia (low blood sugar).

Sagentia was brought into the project as the development partner to provide expertise with Bluetooth Low Energy connectivity between the mobile application and the System. In addition, the team recommended and implemented solutions to provide an enhanced user experience. The final system was delivered within three months, in time for a clinical trial of the first generation product. As a result of the collaboration with Sagentia, the Senseonics system is now capable of extremely fast and reliable communication between the smartphone application and the embedded device, yielding a 10x bandwidth improvement.

Tim Goodnow, CEO at Senseonics, comments: "Sagentia has provided tremendous value in the implementation of the novel Bluetooth Low Energy Technology utilized in our medical mobile app. Sagentia offered to bring in the subject matter expert to meet the company's aggressive timeline and partnered effectively with a start-up medical device company like ours."

The Sagentia team initially conducted a system level review of the transmitter hardware, transmitter firmware and application software. Through this analysis the team identified and significantly improved connection drop outs and low data rates. Sagentia then recommended and implemented several user interface improvements.

With its expertise in smart sensing systems, intelligent algorithms, low power connectivity and big data, Sagentia is actively involved in developing [connected health](#) technologies, which facilitate the management of a patient's condition at a distance. The potential benefits of connected health systems such as this include increased access to specialist knowledge, improved patient compliance with treatment, greater patient mobility, alerts for acute events and easier collection of clinically relevant data outside of clinical settings.

Dr David Pettigrew, Patient Care Sector Manager at Sagentia, adds: "At a time of significant budgetary constraint, healthcare providers must find new ways to reduce costs and increase the efficiency and quality of care. Ensuring underlying health issues are properly addressed and encouraging lifestyle improvements drives reductions in both the number of people visiting healthcare providers and repeat visits. Technology is proving a key enabler in realizing these aims and connected health breakthroughs like Senseonics' could have a really significant impact."

About Sagentia

Sagentia is a global innovation, technology and product development company. We provide outsourced R&D consultancy services to start ups through to global market leaders in the medical, industrial and consumer sectors. With global headquarters in Cambridge, UK, and U.S. headquarters in Boston, Massachusetts, Sagentia works with clients from opportunity discovery through to concept generation and full product development and transfer to manufacture. We excel in science and technology innovation and work with clients to develop next generation products and services that provide commercial value and market advantage. Further information can be found at:

www.sagentia.com

About Senseonics, Inc.

SAGENTIA

Senseonics, Incorporated (formerly Sensors for Medicine and Science, Inc.) is developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics Continuous Glucose Monitoring System is being designed to be the first fully implantable continuous glucose monitoring system that is highly accurate and stable throughout its long sensor life. Senseonics' novel sensor technology may be used to detect other chemical species besides glucose. Medically relevant analytes include oxygen, carbon dioxide, pH, nitric oxide, lactate, and anaesthetic gases. We are well positioned to develop libraries of compounds to detect other small molecules, ions, and biological macromolecules. Our scientists and engineers have considerable expertise in this field and are continually evaluating new opportunities. We can also leverage a range of potential indicators via multiple hardware platforms.

www.senseonics.com

Contact:

Sagentia

Tamara Kahn, +44 1223 875205

Vice President, Corporate Development

Tamara.Kahn@Sagentia.com

Racepoint Group

Nicole Franklin, (617) 624-3223

Account Director

nfranklin@racepointgroup.com